The CPSF73 antibody targets the Cleavage and Polyadenylation Specificity Factor subunit 73 (CPSF73), a critical endonuclease within the pre-mRNA 3′-end processing machinery. CPSF73 is a conserved component of the cleavage and polyadenylation specificity factor (CPSF) complex, essential for RNA polymerase II transcription termination and polyadenylation of eukaryotic mRNAs. It mediates the site-specific cleavage of pre-mRNAs downstream of poly(A) signals, a step required for maturation of most protein-coding transcripts. Structurally, CPSF73 belongs to the β-lactamase family of metallo-β-lactamases, featuring a catalytic zinc-binding domain critical for its enzymatic activity.
Antibodies against CPSF73 are widely used to study its role in transcription termination, pre-mRNA processing, and its interactions with other processing factors (e.g., CPSF100. Symplekin). They have been instrumental in elucidating CPSF73's involvement in diseases, including viral infections where pathogens hijack host polyadenylation machinery, and cancers linked to dysregulated mRNA processing. CPSF73-specific antibodies are typically generated using immunogenic peptide sequences or recombinant protein fragments, validated in applications like Western blotting, immunoprecipitation, and immunofluorescence. Recent studies also highlight CPSF73 as a potential therapeutic target, driving interest in antibodies for functional inhibition assays and structural studies.